Viridian Therapeutics Inc (Viridian), formerly miRagen Therapeutics, focuses on the discovery and development of serious and rare diseases. The company is involved in clinical trials to develop its pipeline products in the therapeutic areas of hematological malignancies, thyroid eye disease, and autoimmune diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Viridian is focused on developing therapeutics targeting validated pathways and disease-driving mechanisms in autoimmune and rare diseases. The company's pipeline includes product candidates directed at the insulin-like growth factor 1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED), inhibitors of the neonatal Fc receptor (FcRn) with potential applications across multiple autoimmune disorders, and a TSHR inhibitor program with potential in TED and Graves’ disease. Viridian Therapeutics Inc develops therapeutics through internal research and discovery, as well as through in-licensing opportunities that align with its strategic focus. The company aims to identify, engineer, and develop potential best-in-class therapeutic proteins and antibodies that optimize patient care, leveraging proven biology on clinically validated targets and internal capabilities such as protein and antibody engineering to reduce development risk while addressing unmet needs for patients. Its R&D activities are managed through internal research and discovery units, as well as through strategic in-licensing opportunities. These units are responsible for protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development, commercial planning, and commercialization in the therapeutic areas of autoimmune and rare diseases. As of December 2025, the company owned three US-issued patents and approximately 22 pending US patents. In FY2025, the company spent US$338,9 million on its R&D activities, which grew 42.2% YoY.